Eko  

1212 Broadway
Suite 100
Oakland,  CA  94612

United States
https://www.ekohealth.com

• Booth: 2137

https://www.ekohealth.com/

Eko exists to ensure all patients have access to early cardiac and pulmonary disease detection and high-quality care that improves and extends their lives. Eko is advancing how healthcare professionals detect and monitor heart and lung disease with its innovative suite of digital tools, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko is headquartered in Oakland, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others.

 Videos

 Press Releases

• Eko Launches Screening Solution to Help Catch Heart Disease Early (Mar 30, 2022)
  Oakland, California

  , 

  March 22, 2022

  Eko, a digital health company advancing heart and lung disease detection, today announced the launch of its newly-redesigned Eko App, which will transform patient interactions into an opportunity to screen for cardiovascular disease. Heart disease is the leading cause of death in the U.S., and there has not been an efficient and affordable solution to screen for heart disease at the physical exam until now.

  “Current clinical workflows for detecting heart disease often include expensive tests performed by a specialist in an emergency setting, which makes early diagnosis nearly impossible,” said Dr. Adam Saltman, Chief Medical Officer, Eko. “The physical exam offers an opportunity for early detection of heart disease. However, as many as 80% of abnormal heart sounds go unrecognized when exams are performed with a traditional stethoscope. This can delay life-saving treatments for patients.”

  Eko has transformed the traditional stethoscope into an intelligent disease detection tool to help clinicians spot cardiovascular disease easier during the physical exam. Their line of smart stethoscopes, when paired with its accompanying automated disease detection software using the Eko App, analyzes heart sounds with FDA-cleared and clinically proven AI algorithms.* In seconds, the algorithms can detect heart murmurs and atrial fibrillation (AFib)** with comparable performance to human experts.     

  “Frontline healthcare professionals are our best line of defense in catching cardiovascular disease early on, but they are challenged to do so by outdated tools, insufficient time, and inadequate resources,” said Connor Landgraf, CEO and Co-founder, Eko. “With a disease that is so pervasive in our society, it is imperative that we provide every healthcare professional with a solution that helps them diagnose with more confidence and give their patients the best care possible. This is how we’ll save millions of lives in the coming years.”

  Eko’s AI algorithm to identify heart murmurs, a leading indicator of heart valve disease, was clinically validated to perform at a sensitivity of 87.6% and specificity of 87.8%. Their algorithm for detecting atrial fibrillation performed at a sensitivity of 98.9% and a specificity of 96.9%. Real-world validation of Eko’s heart murmur detection algorithm came from a recent, peer-reviewed publication in the Journal of the American Heart Association. It was the largest study on AI analysis of cardiac murmurs to date. 

  “Eko’s technology has given me the added assurance to detect and verify heart murmurs and atrial fibrillation in my patients,” said Joanna Kmiecik, MD, Family Medicine Specialist. “The ease-of-use and portable nature of Eko’s products helps me to examine patients right in my office, with minimal impact to my physical examination routine. If I hear a heart sound suspicious of disease, Eko accurately confirms it in seconds. This helps me to determine care decisions and refer to a specialist confidently when appropriate. My patients even enjoy how they can engage with the app, and I feel I am a better clinician.”  

  Join Eko’s community of healthcare professionals using innovative technologies to ensure their patients have access to early heart disease detection that improves and extends their lives.‍

  *For healthcare professional use only‍

  **Atrial fibrillation detection only available when Eko App is used with Eko DUO ECG + Digital Stethoscope‍

  About 

  Eko

  Eko, a digital health company, is advancing how healthcare professionals detect and monitor heart and lung disease with its innovative suite of digital tools, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko is headquartered in Oakland, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others.

  Contact 

  Eko

  Eko Devices, Inc.
  1212 Broadway, Suite 100
  Oakland, CA 94612

• Eko Named to Fast Company’s Annual List of the World’s 50 Most Innovative Companies for 2022 (Mar 30, 2022)
  Oakland, California

  , 

  March 8, 2022

  Eko, a digital health company advancing heart and lung disease detection, has been named to Fast Company’s annual list of the World’s Most Innovative Companies for 2022 in the Medical Device category. Eko’s smart stethoscopes, powered by FDA-cleared artificial intelligence (AI) algorithms, detect leading indicators of cardiovascular disease such as atrial fibrillation (AFib) and heart murmurs at any point of care. This technology provides clinicians with a solution to more efficiently and affordably screen for heart disease, the leading cause of death in the U.S.‍

  Fast Company’s annual list honors businesses that are making the most significant impact on their industries and culture as a whole—ultimately thriving in today’s ever-changing world. These companies are creating the future today with some of the most inspiring accomplishments of the 21st century. Fast Company’s editors and writers sought out the most groundbreaking businesses across the globe and industries. They also judged nominations received through their application process.

  “Eko has achieved numerous milestones over the past year, including doubling our clinician user base, developing novel machine learning technologies, and meeting clinical landmarks,” said Connor Landgraf, Co-Founder and CEO of Eko. “Our team is proud to be recognized by Fast Company as one of the most innovative companies in the world. We are creating a new standard of cardiac care to ensure all patients have early access to heart and lung disease detection.”

  Real-world validation of Eko’s AI algorithms came from a peer-reviewed publication in the Journal of the American Heart Association that found the performance of Eko’s AI for detecting heart murmurs comparable to human experts. It was the largest study on AI analysis of cardiac murmurs to date. In conjunction with the UK National Health Service (NHS), a groundbreaking independent study by the Imperial College of London demonstrated Eko’s ability to screen patients for heart failure in seconds using AI during routine physical exams. 

  The World’s Most Innovative Companies is Fast Company’s signature franchise and one of its most highly anticipated editorial efforts of the year. It provides both a snapshot and a road map for the future of innovation across the economy's most dynamic sectors.

  “The world’s most innovative companies play an essential role in addressing the most pressing issues facing society, whether they’re fighting climate change by spurring decarbonization efforts, ameliorating the strain on supply chains, or helping us reconnect with one another over shared passions,” said Fast Company Deputy Editor, David Lidsky.‍

  Fast Company’s Most Innovative Companies issue (March/April 2022) is available online here, as well as in-app form via iTunes, and on newsstands beginning March 15.‍

  About Eko‍

  Eko, a digital health company, is changing how healthcare professionals detect and monitor heart and lung disease with its innovative suite of digital tools, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko is headquartered in Oakland, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. To learn more about Eko, visit ekohealth.com.‍

  About Fast Company‍

  Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at www.fastcompany.com.

  About 

  Eko

  Eko, a digital health company, is advancing how healthcare professionals detect and monitor heart and lung disease with its innovative suite of digital tools, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko is headquartered in Oakland, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others.

  Contact 

  Eko

  Eko Devices, Inc.
  1212 Broadway, Suite 100
  Oakland, CA 94612

• Eko Welcomes Eric Davidson as President (Mar 30, 2022)
  Oakland, CA

  , 

  February 23, 2022

  Eko, a digital health company advancing heart and lung disease detection, today announced the appointment of Eric Davidson as President and Chief Operating Officer. Davidson joins Eko from Johnson & Johnson, where he served as President of Flexible Robotics following the company’s $3.4 billion acquisition of Auris Health. 

  “Eric’s extensive background in the medtech industry will be an invaluable asset as we work to bring early cardiac and pulmonary disease detection to the masses,” said Connor Landgraf, CEO and co-founder, Eko. “We are on a mission to put our technology in the hands of every healthcare professional, giving them the ability to screen patients at any point of care.”

  Davidson’s appointment follows a year of significant milestones for Eko. The company doubled its clinical user base of healthcare professionals, and with continued engagement from investors recently extended its Series C funding to a total of $125M raised. In January, the NHS published a landmark independent study validating Eko’s ability to screen patients for heart failure in seconds with AI during routine physical exams. 

  "My passion for the transformative potential of Eko's technology has me incredibly excited to join Eko’s exceptional leadership team,” said Davidson. “Eko is uniquely positioned to enable earlier and more accurate diagnosis of heart and lung disease, to democratize the diagnosis itself, and to unlock powerful, innovative ways for healthcare providers and professionals to reach and manage patients."

  Prior to joining Auris Health, Davidson led Product Marketing for Intuitive Surgical, and helped to bring minimally invasive robotic-assisted surgery to physicians and patients around the world.

  "Eric's operating and commercial leadership at multiple industry-defining companies makes him the ideal steward for Eko’s next phase of growth", said Vasudev Bailey, PhD., Board Chair at Eko and Senior Partner at ARTIS Ventures. “We are delighted to welcome aboard a President who shares our passion for elevating the standard of cardiopulmonary care”

  About 

  Eko

  Eko, a digital health company, is advancing how healthcare professionals detect and monitor heart and lung disease with its innovative suite of digital tools, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko is headquartered in Oakland, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others.

  Contact 

  Eko

  Eko Devices, Inc.
  1212 Broadway, Suite 100
  Oakland, CA 94612

• NHS Study Demonstrates Eko Smart Stethoscope Can Identify Heart Failure (Mar 30, 2022)
  Oakland, California

  , 

  February 1, 2022

  Eko, a digital health company advancing heart and lung disease detection, announced today that the Imperial College of London, in conjunction with the UK National Health Service (NHS), published a study(1) which highlights Eko’s ability to screen patients for heart failure in seconds with AI during physical exams.

  Eko’s low ejection fraction algorithm (ELEFT) detects a weakened heart pump, which is present in about half of heart failure patients.(2) It was developed in collaboration with the Mayo Clinic and will be submitted to the FDA under “Breakthrough Designation” for formal review later this year. 

  “This tool allows healthcare professionals to reliably rule in or rule out heart failure at the point of care,” said Dr. Nicholas Peters, Professor of Cardiology, Imperial College London. “The result will be earlier diagnosis and treatment and the avoidance of unnecessary and expensive tests for those in whom heart failure is ruled out. This means better and more cost-effective healthcare. It’s a total game-changer."

  According to the American Heart Association, 6 million American adults are estimated to have heart failure,(3) with 26 million people affected worldwide.(4) Diagnosis is a significant challenge given that heart failure symptoms are also associated with many other conditions and detection often requires a series of expensive tests. Using the Eko DUO ECG + Digital Stethoscope with ELEFT, heart failure caused by a weakened heart pump can be detected in seconds during a stethoscope exam.

  “The superhuman capability to screen patients at any point of care, including before surgery, should challenge the unacceptable reality that 80% of patients with heart failure are currently diagnosed through an emergency hospital admission,” said Dr. Patrick Bachtiger, lead author and a clinical research fellow at the UK’s National Heart and Lung Institute. “The current clinical pathway simply misses too many patients, leaving them undiagnosed until very sick. This tool can save time and money and unlock major benefits for patients through early diagnosis and effective treatments."

  In the study, the algorithm’s performance at detecting a weak heart pump was excellent compared to the current gold standard of echocardiography.​​ When 15-second recordings were taken with the DUO at one chest location, the algorithm was 81% accurate at identifying normal and impaired heart pumping function. Accuracy went up to 86% when two recording locations were used. 

  “This is a landmark study for multiple reasons,” said Dr. Adam Saltman, Chief Medical Officer at Eko. “The investigators showed that the low ejection fraction detection algorithm can quickly, easily, and effectively identify the patients who have impaired heart pumping function, even if those patients don’t yet have symptoms.”

  ‍References

  1. Bachtiger, Patrik et al. Point-of-care screening for heart failure with reduced ejection fraction using artificial intelligence during ECG-enabled stethoscope examination in London, UK: a prospective, observational, multicentre study. Lancet Digit Health, S2589-7500(21)00256-9. 5 Jan. 2022, doi:10.1016/S2589-7500(21)00256-9

  2. Borlaug, B. A., & Redfield, M. M. (2011). Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation, 123(18), 2006–2014. https://doi.org/10.1161/CIRCULATIONAHA.110.954388

  3. Benjamin EJ, et al. Heart Disease and Stroke Statistics— 2018 Update: a report from the American Heart Association. Circulation, 2018;137(12):e67-e492

  4. Saravese G, et al. Global public health burden of heart failure. Card Fail Rev, 2017;3(1):7-11. doi: 10.15420/cfr.2016:25:2.

  About 

  Eko

  Eko, a digital health company, is advancing how healthcare professionals detect and monitor heart and lung disease with its innovative suite of digital tools, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko is headquartered in Oakland, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others.

  Contact 

  Eko

  Eko Devices, Inc.
  1212 Broadway, Suite 100
  Oakland, CA 94612

• Eko’s AI Analysis Algorithm Validated as a Clinical Tool for Detecting Heart Murmurs (Mar 30, 2022)
  Oakland, California 

  , 

  May 11, 2021

  OAKLAND, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Eko, a cardiopulmonary digital health company, today announced the peer-reviewed publication of a clinical study that found that the Eko artificial intelligence (AI) algorithm for detecting heart murmurs is accurate and reliable, with comparable performance to that of an expert cardiologist. The findings suggest utility of the FDA-cleared Eko AI algorithm as a frontline clinical tool to aid clinicians in screening for cardiac murmurs that may be caused by valvular heart disease.

  Algorithm performance for detecting murmurs was found to have sensitivity of 90.0% and specificity of 91.4%, when excluding grade 1 murmurs which are difficult to hear. The NIH-sponsored, multisite study published in the Journal of the American Heart Association was the largest study on AI analysis of cardiac murmurs. Study investigators included collaborators from Northwestern Memorial Hospital, University of California San Francisco Medical Center, Los Alamitos Cardiology Clinic, and Mount Sinai Medical Center.

  “When it comes to listening for heart murmurs, the standard of care involves a lot of subjectivity on the part of the listener,” said John Maidens, PhD, head of Data Science at Eko. “It takes expert clinicians many years to master the art of hearing and interpreting heart murmurs, and there is still a lot of variability. Our study demonstrated considerable variability even among our expert cardiologists.”

  “We designed the study to see whether the algorithm could not only identify murmurs in an experimental setting, but whether it could help clinicians actually make difficult diagnostic decisions at the bedside. And that’s what the results show,” said Dr. John Chorba, lead author of the study and cardiologist at the University of California San Francisco. “I’m incredibly excited because this may just be the tip of the iceberg with the technology, and as it gets more widely used, we’ll get to see how much further it can take us in diagnosing heart disease.”

  For moderate-to-severe aortic stenosis, the algorithm was found to have sensitivity of 93.2% and specificity of 86.0%. The algorithm significantly outperformed general practitioners listening for moderate-to-severe valvular heart disease, as a 2018 study showed general practitioners had sensitivity of 44% and specificity of 69%.

  “We are thrilled by how Eko’s digital stethoscopes with Eko AI analysis can help any frontline provider discover meaningful, clinically important cardiac murmurs at the point of care,” said Dr. Adam Saltman, chief medical officer at Eko. “By detecting heart disease earlier, patients can be treated earlier. Costs are typically lower, outcomes are better, and they are more likely to retain a better quality of life. Appropriate patients can be referred to specialists for care when they need it. In addition, the high specificities mean that healthy patients will be much less likely to have unnecessary testing.”

  “The stethoscope has changed remarkably little in its 200+ year history,” said Dr. James Thomas, director of the Center for Heart Valve Disease at Bluhm Cardiovascular Institute at Northwestern Medicine and senior author to the study. “Now for the first time, artificial intelligence is being applied to stethoscopic heart sounds to improve the auscultation skills of health care professionals. This technology has the promise to extend this expertise to all clinicians.”

  About Eko
  Eko, a cardiopulmonary digital health company, is elevating the way clinicians detect and monitor cardiac and respiratory disease by bringing together advanced sensors, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of clinicians treating millions of patients around the world, in-person and through telehealth. The company is headquartered in Oakland, California, with investments from Highland Capital Partners, Questa Capital, Artis Ventures, NTTVC, DigiTx Partners, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

  Media Contact:

  Brit Gould
  VP, Product Marketing
  Eko
  brit.gould@ekohealth.com

 Additional Info